Please assess the completion status of the following clinical trial:

Trial Title: Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Polyuria of \> 50 ml/Kg/day~* Polydipsia of \> 3 liters/day~Exclusion Criteria:~* Known or probable central or nephrogenic Diabetes insipidus, expected from patient's history~* Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia~* Pregnancy~* Previous treatment with GLP-1 agonists within the last 3 month~* History of pancreatitis~* Severe renal insufficiency (eGFR (CKD EPI) \<30 ml/min/1,73 m2)~* Cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Verum first (Type: EXPERIMENTAL): Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
- Placebo first (Type: PLACEBO_COMPARATOR): Placebo: 0.5 ml normal saline (0.9% sodium chloride \[0.9% sodium chloride (NaCl)\]), injection sc via syringe once weekly for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).